
    
      This is a single-center, nonrandomized, open-label, 2-period, 1-sequence crossover study to
      investigate the safety, tolerability and pharmacokinetics of VX 770 when administered alone
      or with rifampin.

      All enrolled subjects will receive the same treatments and undergo the same procedures. In
      Period 1, subjects will receive a single dose of VX 770 on Day 1. In Period 2, subjects will
      receive a daily dose of rifampin on Days 1 through 10 and a single dose of VX 770 on Day 6.
    
  